Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
暂无分享,去创建一个
[1] C. Scallan,et al. Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties , 2005, Journal of Virology.
[2] H. Mizukami,et al. Induction of Robust Immune Responses against Human Immunodeficiency Virus Is Supported by the Inherent Tropism of Adeno-Associated Virus Type 5 forDendritic Cells , 2006, Journal of Virology.
[3] B. Beutler,et al. The interface between innate and adaptive immunity , 2004, Nature Immunology.
[4] Dongsheng Duan,et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors , 2005, Nature Biotechnology.
[5] S. Hensley,et al. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. , 2007, The Journal of clinical investigation.
[6] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[7] R. Morgan,et al. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. , 1999, Blood.
[8] H. Sweeney,et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. , 2001, Human gene therapy.
[9] R. Herzog,et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. , 2007, Blood.
[10] M. Carroll,et al. The complement system in B cell regulation. , 2004, Molecular immunology.
[11] J. Sommer,et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. , 2006, Blood.
[12] Lili Wang,et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] Michael Karin,et al. Intracellular pattern recognition receptors in the host response , 2006, Nature.
[14] A. Varki,et al. Loss of Siglec expression on T lymphocytes during human evolution , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Herzog,et al. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. , 2004, Blood.
[16] C. Lilley,et al. APOBEC3A Is a Potent Inhibitor of Adeno-Associated Virus and Retrotransposons , 2006, Current Biology.
[17] R. Samulski,et al. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection , 1999, Nature Medicine.
[18] D. Duan,et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. , 2000, The Journal of clinical investigation.
[19] Luis Garcia,et al. Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping , 2004, Science.
[20] K. High. Update on progress and hurdles in novel genetic therapies for hemophilia. , 2007, Hematology. American Society of Hematology. Education Program.
[21] M. Kay,et al. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. , 2003, Current gene therapy.
[22] Daniel G. Miller,et al. Gene targeting in vivo by adeno-associated virus vectors , 2006, Nature Biotechnology.
[23] K. High,et al. Immune responses to AAV in clinical trials. , 2007, Current gene therapy.
[24] M. Kay,et al. The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9 , 2006, Journal of Virology.
[25] J. Atkinson,et al. T-cell regulation: with complements from innate immunity , 2007, Nature Reviews Immunology.
[26] D. Koeberl,et al. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. , 2007, American journal of human genetics.
[27] R. Herzog,et al. Muscle as a target for supplementary factor IX gene transfer. , 2007, Human gene therapy.
[28] R. Samulski,et al. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. Herzog,et al. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer , 2005, Gene Therapy.
[30] James M. Wilson,et al. Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers , 1998, Journal of Virology.
[31] R. Coppel,et al. AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. , 2007, Vaccine.
[32] H. Morizono,et al. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] Reuben S. Harris,et al. Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.
[34] James M. Wilson,et al. Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle , 2000, Journal of Virology.
[35] D. Koeberl,et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] M. Carroll,et al. The complement system in regulation of adaptive immunity , 2004, Nature Immunology.
[37] James M. Wilson,et al. Vaccines Based on Novel Adeno-Associated Virus Vectors Elicit Aberrant CD8+ T-Cell Responses in Mice , 2007, Journal of Virology.
[38] Prerna Sharma,et al. Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue , 1998, Journal of Virology.
[39] J. F. Wright,et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. , 2007, Blood.
[40] Z. Xiang,et al. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[41] L. Couto,et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. , 2006, Blood.
[42] C. Walker,et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D , 1997, Journal of virology.
[43] James M. Wilson,et al. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered , 2006, Proceedings of the National Academy of Sciences.
[44] R. Desnick,et al. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[45] Lili Wang,et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Gray,et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. , 2007, Blood.
[47] Theresa A. Storm,et al. Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.
[48] R. Balice-Gordon,et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector , 1999, Nature Medicine.
[49] J. Emerson,et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. , 2006, Human gene therapy.
[50] R. Snyder. Adeno‐associated virus‐mediated gene delivery , 1999, The journal of gene medicine.
[51] R. Herzog,et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.
[52] J. Sommer,et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. , 2006, Blood.
[53] S. Bidlingmaier,et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[54] Giovanni Di Pasquale,et al. Identification of PDGFR as a receptor for AAV-5 transduction , 2003, Nature Medicine.
[55] F. Bosch,et al. Reversal of Type 1 Diabetes by Engineering a Glucose Sensor in Skeletal Muscle , 2006, Diabetes.
[56] Theresa A. Storm,et al. Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectors , 2004, Journal of Virology.
[57] J. Tschopp,et al. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. , 2006, Molecular cell.
[58] S. Hensley,et al. Toll-like receptors impact on safety and efficacy of gene transfer vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[59] H. Mizukami,et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. , 2001, Human gene therapy.
[60] R. Mandel,et al. Circulating Anti-Wild-Type Adeno-Associated Virus Type 2 (AAV2) Antibodies Inhibit Recombinant AAV2 (rAAV2)-Mediated, but Not rAAV5-Mediated, Gene Transfer in the Brain , 2004, Journal of Virology.
[61] A. Heguy,et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[62] C. Halbert,et al. Successful Readministration of Adeno-Associated Virus Vectors to the Mouse Lung Requires Transient Immunosuppression during the Initial Exposure , 1998, Journal of Virology.
[63] J. Rasko,et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.
[64] James M. Allen,et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[65] R. Samulski,et al. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. , 1999, Nature medicine.
[66] O. Danos,et al. Successful Interference with Cellular Immune Responses to Immunogenic Proteins Encoded by Recombinant Viral Vectors , 2001, Journal of Virology.
[67] H. Ertl,et al. Identification of mouse AAV capsid-specific CD8+ T cell epitopes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[68] S. Heikkinen,et al. Type I interferon response against viral and non‐viral gene transfer in human tumor and primary cell lines , 2007, The journal of gene medicine.
[69] H. Lutz,et al. Complement amplification revisited. , 2006, Molecular immunology.
[70] R. Samulski,et al. Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In Vivo , 2007, Journal of Virology.
[71] Shangzhen Zhou,et al. Mutations on the External Surfaces of Adeno-AssociatedVirus Type 2 Capsids That Affect Transduction andNeutralization , 2006, Journal of Virology.
[72] D. Bohl,et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. , 1997, Human gene therapy.
[73] M. Ozelo,et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[74] Yuqin Wang,et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. , 2003, The Journal of clinical investigation.
[75] K. High,et al. Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[76] Ravi A. Desai,et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid , 2006, Nature Medicine.
[77] Mary J. Connell,et al. Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques , 2005, Journal of Virology.
[78] Katherine A. High,et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.
[79] C. Slaughter,et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. , 2002, Blood.
[80] Robert B Sim,et al. Functional Significance of Factor H Binding to Neisseria meningitidis1 , 2006, The Journal of Immunology.
[81] N. Wong,et al. Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors , 2008, Journal of Virology.
[82] R. Herzog,et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. , 2002, Human gene therapy.
[83] James M. Wilson,et al. AAV as an immunogen. , 2007, Current gene therapy.
[84] S. Tapscott,et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. , 2006, Human gene therapy.
[85] W. Hauswirth,et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[86] O. Danos,et al. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice , 2006, Gene Therapy.
[87] Yi Zhang,et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. , 2004, Blood.
[88] D. Schaffer,et al. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors , 2006, Nature Biotechnology.
[89] M. Hallek,et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies , 2003, Gene Therapy.
[90] J. Engelhardt,et al. Ubiquitination of both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors , 2002, Journal of Virology.
[91] Keyun Qing,et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 , 1999, Nature Medicine.
[92] R. Jessberger,et al. Precise hit: adeno-associated virus in gene targeting , 2005, Nature Reviews Microbiology.
[93] James M. Wilson,et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[94] R. Samulski,et al. Autoimmune anemia in macaques following erythropoietin gene therapy. , 2004, Blood.
[95] N. Wong,et al. Differential Activation of Innate Immune Responses by Adenovirus and Adeno-Associated Virus Vectors , 2002, Journal of Virology.
[96] Marcela V Maus,et al. CD8+ T-cell responses to adeno-associated virus capsid in humans , 2007, Nature Medicine.